Blueprint Medicines(BPMC) - 2023 Q2 - Earnings Call Transcript

Our execution across a diverse set of value drivers in the first half of this year has set us on a strong trajectory for continued success moving into the second half of 2023. Our number one priority will continue to be driving revenue acceleration with the launch of AYVAKIT and SM. While we also progress our pipeline of programs addressing some of the most important and exciting biological targets in oncology and allergy immunology that have the potential to impact large number of patients globally. While ...